Analysis of CYP2D6 genotypes in malaria patients reveals 25% poor metabolizers, suggesting adjustments to primaquine dosing.
We determined CYP2D6*4 and CYP2D6* genotypes and metabolizer phenotypes in 96 patients with suspected malaria in Venezuela and found intermediate or poor metabolizer phenotypes in ≈25% of cases. Nine of 44 malaria patients had Plasmodium vivax recurrence. Public health authorities should evaluate the benefits of increasing total doses of primaquine for treatment.
No takes yet. Share an insight, caveat, or question.
Pacheco et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: